FDA finalises guide for ANDA content

Guidance intended to assist applicants in preparing abbreviated new drug applications (ANDAs) for submission to the US Food and Drug Administration (FDA), identifying the information “that an applicant should include to ensure that a complete, high-quality application is submitted to FDA”, has been finalised by the US agency.